ArticleBioactive materials2027
Biomimetic sequential targeted nanoplatform for synergistic thrombolysis in ischemic stroke.
Article in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional thrombolytic drugs for vascular blockage such as tissue plasminogen activator (tPA) are challenged by the low bioavailability, off-target side effects and limited penetration in thrombi, leading to delayed recanalization. Herein, we developed a sequential targeted nanoplatform for efficient thrombolysis based on the thrombolysis-neuroprotection integrated strategy. The mesoporous silica layer-modified upconversion nanoparticle (UCNP) was loaded with the nitric oxide (NO) donors (BNN6), further coating platelet membranes (PMs) on the surface of UCNP. tPA was conjugated onto PMs using the MMP9-responsive peptide as a linker to form a multifunctional drug carrier of UCNP/BNN6@PM-tPA. The proposed drug carrier maintained stability in the blood circulation to reduce bleeding risk (protection), facilitating it colonizing at the thrombus clots. MMP-9 triggered the release of tPA to realize rapid thrombolysis (attack), whereas continuous NO release from NIR-irradiated BNN6 acted to prevent vascular re-embolization (defense).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.